Cargando…

Characteristics of and meningococcal disease prevention strategies for commercially insured persons receiving eculizumab in the United States

INTRODUCTION: Eculizumab is a licensed treatment for several rare, complement-mediated diseases. Eculizumab use is associated with an approximately 2,000-fold increased meningococcal disease risk. In the United States, meningococcal vaccines are recommended for eculizumab recipients but there are no...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bozio, Catherine H., Isenhour, Cheryl, McNamara, Lucy A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7660549/ https://www.ncbi.nlm.nih.gov/pubmed/33180804 http://dx.doi.org/10.1371/journal.pone.0241989

Ejemplares similares

Differences in meningococcal disease incidence by health insurance type and among persons experiencing homelessness—United States, 2016–2019
por: Isenhour, Cheryl J., et al.
Publicado: (2023)

High Risk for Invasive Meningococcal Disease Among Patients Receiving Eculizumab (Soliris) Despite Receipt of Meningococcal Vaccine
por: McNamara, Lucy A., et al.
Publicado: (2017)

Fatal Nongroupable Neisseria meningitidis Disease in Vaccinated Patient Receiving Eculizumab
por: Nolfi-Donegan, Deirdre, et al.
Publicado: (2018)

Notes from the Field: Increase in Meningococcal Disease Among Persons with HIV — United States, 2022
por: Rubis, Amy B., et al.
Publicado: (2023)

Concerns about unapproved meningococcal vaccination for eculizumab therapy in Japan
por: Tanimoto, Tetsuya, et al.
Publicado: (2014)

Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020
por: Mbaeyi, Sarah A., et al.
Publicado: (2020)

Hepatitis B Virus Testing and Care among Pregnant Women Using Commercial Claims Data, United States, 2011–2014
por: Harris, Aaron M., et al.
Publicado: (2018)

1558. Commensal Neisseria Species as a Cause of Disease in Patients Taking Eculizumab
por: Crew, Page, et al.
Publicado: (2018)

University-Based Outbreaks of Meningococcal Disease Caused by Serogroup B, United States, 2013–2018
por: Soeters, Heidi M., et al.
Publicado: (2019)

636. Meningococcal Vaccination and Antibiotic Prophylaxis Practices in Solid Organ Transplant Recipients undergoing Eculizumab Therapy
por: Bhaimia, Eric, et al.
Publicado: (2022)

Meningococcal Disease Surveillance in Men Who Have Sex with Men — United States, 2015–2016
por: Bozio, Catherine H., et al.
Publicado: (2018)

Risk Analysis of Eculizumab-Related Meningococcal Disease in Japan Using the Japanese Adverse Drug Event Report Database
por: Matsumura, Yumi
Publicado: (2020)

HIV Testing Trends Among Persons with Commercial Insurance or Medicaid — United States, 2014–2019
por: Henny, Kirk D., et al.
Publicado: (2021)

Tetanus, Diphtheria, and Acellular Pertussis Vaccination Coverage Among Publicly Insured Pregnant Women, U.S., 2016–2019
por: Isenhour, Cheryl J., et al.
Publicado: (2022)

Surveillance and control of meningococcal disease in the COVID-19 era: A Global Meningococcal Initiative review
por: Alderson, Mark R., et al.
Publicado: (2022)

Principles of risk management and insurance
por: Rejda, George E, et al.
Publicado: (2013)

Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab
por: Wijnsma, Kioa Lente, et al.
Publicado: (2019)

Sporotrichosis Cases in Commercial Insurance Data, United States, 2012–2018
por: Benedict, Kaitlin, et al.
Publicado: (2020)

Postpartum care visits among commercially insured women in the United States
por: Butwick, Alexander J., et al.
Publicado: (2022)

Economic Burden of HIV in a Commercially Insured Population in the United States
por: Chen, Cindy Y., et al.
Publicado: (2023)

Epidemiology of rhegmatogenous retinal detachment in commercially insured myopes in the United States
por: Ludwig, Cassie A., et al.
Publicado: (2023)

Eculizumab for the treatment of glycine receptor antibody associated stiff-person syndrome
por: McCombe, Jennifer A., et al.
Publicado: (2023)

Vaccination strategies for the prevention of meningococcal disease
por: Vuocolo, Scott, et al.
Publicado: (2018)

Causes of Death among Commercially Insured Multiple Sclerosis Patients in the United States
por: Goodin, Douglas S., et al.
Publicado: (2014)

Presumed ocular histoplasmosis syndrome in a commercially insured population, United States
por: Benedict, Kaitlin, et al.
Publicado: (2020)

Healthcare Utilization and Cost Burden of Porphyria in Commercially Insured Adults in the United States
por: Elsaid, Mohamed I., et al.
Publicado: (2020)

Serogroup B Meningococcal Disease Vaccine Recommendations at a University, New Jersey, USA, 2016
por: Soeters, Heidi M., et al.
Publicado: (2017)

Eculizumab Dosing in Infants
por: Kobrzynski, M., et al.
Publicado: (2018)

Genomic Insights on Variation Underlying Capsule Expression in Meningococcal Carriage Isolates From University Students, United States, 2015–2016
por: Whaley, Melissa J., et al.
Publicado: (2022)

Serogroup B Meningococcal Disease Outbreak and Carriage Evaluation at a College — Rhode Island, 2015
por: Soeters, Heidi M., et al.
Publicado: (2015)

Genetic Diversity of Meningococcal Serogroup B Vaccine Antigens among Carriage Isolates Collected from Students at Three Universities in the United States, 2015–2016
por: Marjuki, Henju, et al.
Publicado: (2021)

Patient characteristics, treatment patterns, and outcomes of Rickettsial diseases among a commercially insured population in the United States, 2005–2017
por: Binder, Alison M., et al.
Publicado: (2021)

Use of MenACWY-CRM Vaccine in Children Aged 2 Through 23 Months at Increased Risk for Meningococcal Disease: Recommendations of the Advisory Committee on Immunization Practices, 2013
por: MacNeil, Jessica R., et al.
Publicado: (2014)

The Burden of Infant Meningococcal Disease in the United States
por: Judelsohn, R., et al.
Publicado: (2012)

Risk factors for invasive meningococcal disease: a retrospective analysis of the French national public health insurance database
por: Taha, Muhamed-Kheir, et al.
Publicado: (2021)

Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use
por: Wijnsma, Kioa L., et al.
Publicado: (2018)

Care pathways in invasive meningococcal disease: a retrospective analysis of the French national public health insurance database
por: Weil-Olivier, Catherine, et al.
Publicado: (2022)

Healthcare Resource Consumption and Cost of Invasive Meningococcal Disease in France: A Study of the National Health Insurance Database
por: Weil-Olivier, Catherine, et al.
Publicado: (2021)

Coccidioidomycosis Skin Testing in a Commercially Insured Population, United States, 2014–2017
por: Benedict, Kaitlin, et al.
Publicado: (2020)

Direct and Indirect Costs of Infectious Conjunctivitis in a Commercially Insured Population in the United States
por: Pepose, Jay S, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_c695r4pmc2hru6g09b8urd4tq2